Cardiff Oncology Advances Onvansertib into Phase 3 Trial After Positive ASCO Data — Cardiff Oncology, Inc.

Event summary

Cardiff Oncology presented positive Phase 2 CRDF-004 data at ASCO, showing a 30% ORR improvement over standard-of-care in first-line RAS-mutated mCRC.
The company completed a $10 million registered direct offering to extend its cash runway into Q3 2027.
Cardiff aligned with the FDA on key design elements for its planned Phase 3 trial, targeting initiation in Q1 2027 subject to securing additional financing.

The big picture

Cardiff Oncology's advancement of onvansertib into a Phase 3 trial marks a critical step in addressing the significant unmet need in first-line RAS-mutated metastatic colorectal cancer. The positive Phase 2 data and FDA alignment position the company favorably, but securing financing remains a key hurdle. The biotech sector continues to focus on targeted therapies, with PLK1 inhibition emerging as a promising avenue for overcoming treatment resistance.

What we're watching

Execution Risk: Whether Cardiff can secure additional financing to initiate the Phase 3 trial as planned in Q1 2027.
Regulatory Dynamics: The pace at which the FDA will review and approve the Phase 3 trial design, given the positive Phase 2 data.
Market Positioning: How Cardiff's onvansertib compares to emerging therapies in the RAS-mutated mCRC space as it progresses toward registration.